KaNDy Therapeutics company

KaNDy Therapeutics develops a breakthrough non-hormonal treatment for multiple symptoms of the menopause including hot flashes and nighttime awakening. Launched in 2017, KaNDy Therapeutics is a UK based clinical-stage company focused on optimizing the potential of its unique NK-1,3 receptor antagonist NT-814 in the treatment of common, chronic debilitating female sex-hormone related conditions. NT-814 is a unique, first-in-class dual mechanism NK-1,3 antagonist therapy dosed orally once daily. It has the potential to be a true breakthrough non-hormonal alternative to hormone replacement therapy (HRT). NT-814 has successfully completed a Phase 2a proof of concept study demonstrating its potential to rapidly and profoundly reduce two key symptoms of the menopause: hot flashes and night time awakening. Preparations are underway for a multi-country Phase 2b study with NT-814 in this anchor Women’s Health indication, starting in Q4 2018. KaNDy Therapeutics is based at the state-of-the-art Stevenage Bioscience Catalyst, the UK’s first open innovation bioscience campus.
Technology: Longevity FemTech
Industry: FemTech
Headquarters: Stevenage, Herefordshire, United Kingdom
Founded Date: 7-9
Employees Number: 1-10
Funding Status: Late Stage Venture
Investors Number: 5
Total Funding: £25M
Estimated Revenue: $1M to $10M
Last Funding Type: Series C

Visit Website
info@kandytherapeutics.com
twitter.com/kandybiotech
Register and Claim Ownership